MONDAY, June 8, 2026 (HealthDay News) -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with reduced risks for thromboembolic events, emergency department use, and mortality among adults with obesity and autoimmune diseases (AIDs), according to a study published online June 6 in the Journal of the American Heart Association to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.Hao Dai, Ph.D., from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a retrospective cohort study, which emulated a target trial using 2014 to 2024 electronic health record data to examine the association between GLP-1 RA use and major adverse cardiovascular and thromboembolic event risk among adults with obesity and AID
Growth hormone/IGF-1 axis supports bone and cartilage metabolism (established endocrinology)
Biodisponibilidad de GHK-Cu La biodisponibilidad es la cantidad de un compuesto que realmente llega al torrente sanguneo y se vuelve utilizable por el cuerpo
Additional research into other novel biomarkers to more precisely pinpoint MDD diagnosis could ultimately lead to a different way of thinking about treatments for MDD and other disorders. Rasgon adds: We are excited about this first translational study in humans, and poised to build on our results to identify new treatment targets in the brain. Funding: Robertson Foundation, Hope for Depression Research Foundation, Pritzker Neuropsychiatric Disorders Research Consortium, Pritzker Neuropsychiatric Disorders Research Fund funded this study
Healthcare in Louisiana warrants correct usage to increase insurance approval chances
At TrimRx, your safety is paramount, and our medically supervised programs are designed to monitor your health closely